Skip to content
Biotechnology, Engineering

A better ‘map’ of the lights you see when you close your eyes can improve ‘bionic eye’ outcomes

Monash University 2 mins read

Researchers at Monash University have identified a new way of mapping ‘phosphenes’ – the visual perception of the bright flashes we see when no light is entering the eye – to improve the outcome of surgery for patients receiving a cortical visual prosthesis (‘bionic eye’).

 

Cortical visual prostheses are devices implanted onto the brain with the aim of restoring sight by directly stimulating the area responsible for vision, the visual cortex, bypassing damage to the retina of the eye or the optic nerve.

 

A typical prosthesis consists of an array of fine electrodes, each of which is designed to trigger a phosphene. Given the limited number of electrodes, understanding how electrodes can best be placed to generate useful perceived images becomes critical.

 

As part of this, researchers from the Department of Electrical and Computer Systems Engineering at Monash University, led by Associate Professor Yan Tat Wong, are honing in on the ideal distribution of phosphenes.

 

“Phosphenes are likely to be distributed unevenly in an individual’s visual field, and differences in the surface of the brain also affect how surgeons place implants, which together result in a phosphene map unique to each patient,” Associate Professor Wong said.

 

Published in the Journal of Neural Engineering, ‘A novel simulation paradigm utilising MRI-derived phosphene maps for cortical prosthetic vision’ presents a more realistic simulation for cortical prosthetic vision.

The study used a retinotopy dataset based on magnetic resonance imaging (MRI) scans, consulting with a neurosurgeon about realistic electrode implantation sites in different individuals, and applying a clustering algorithm to determine the most suitable regions to present stimuli.

 

Sighted participants recruited for the study were asked to test and verify the phosphene maps based on visual acuity and object recognition. 

 

“We’re proposing a new process that incorporates our simulation paradigm into surgical planning to help optimise the implantation of a cortical prosthesis,” Associate Professor Wong said.

 

The process would begin with an MRI scan to plot the recipient’s brain surface in the area of the visual cortex. Potential implant locations would then be identified, and the simulation developed in the Monash research would be used to plot phosphene maps.

 

“We can use the metrics we computed to find practical implant locations that are more likely to give us a usable phosphene map, and we can verify those options through psychophysics tests on sighted participants using a virtual reality headset,” Associate Professor Wong said.

 

“We believe this is the first approach that realistically simulates the visual experience of cortical prosthetic vision.” 

- ENDS -

 

MEDIA ENQUIRIES

Loretta Wylde

Monash University

Media and Communications

E: loretta.wylde@monash.edu

T: +61 (0) 432 123 106

 

GENERAL MEDIA ENQUIRIES

Monash Media

T: +61 (0) 3 9903 4840

E: media@monash.edu

For more Monash media stories, visit our news and events site 

Media

More from this category

  • Biotechnology
  • 17/10/2024
  • 06:08
Dementia Australia

Rejection of drug a blow for Australians living with Alzheimer’s disease

Dementia Australia is disappointed by the initial decision of the Therapeutic Goods Administration (TGA) to reject Lecanemab for use in Australia. Lecanemab is a disease modifying treatment for people living with the early stages of Alzheimer’s disease or mild cognitive impairment. Developed by pharmaceutical company Eisai, Lecanemab works by removing amyloid plaques from the brain and in doing so slows cognitive decline associated with the disease. Lecanemab is currently approved for use in the UK, USA, Japan, China, South Korea, Hong Kong, United Arab Emirates and Israel. In July it was rejected by the European Medicines Agency, a decision that…

  • Biotechnology
  • 17/10/2024
  • 00:10
Athos Therapeutics

Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells

ATH-063 significantly increased the number of circulating regulatory T cells (Tregs) across all doses and demonstrated enrichment in six well-described genes related to induced Treg anti-inflammatory activitiesNo serious adverse effects or dose limiting toxicities were observed at any dose level, and ATH-063 demonstrated favorable pharmacokinetics (PK) The data provides clinical verification for Athos' Proprietary AI2 (Artificial Intelligence for Autoimmune drug development) computational software platform which generated ATH-063 LOS ANGELES, CA / ACCESSWIRE / October 16, 2024 / Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, today…

  • Biotechnology
  • 16/10/2024
  • 21:10
Moolec Science SA

Moolec Has Received USDA Approval for the First Genetically Modified Pea in History

LUXEMBOURG / ACCESSWIRE / October 16, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance from USDA-APHIS achieved by Moolec in an 18-month window, alongside its genetically engineered safflower and soybean for GLASO™ and Piggy Sooy™ products, respectively. Access the official USDA-APHIS publication here. "With USDA approval for our GE pea, Moolec…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.